Robert W. Baird upgrades Biogen Idec (Nasdaq: BIIB) from Neutral to Outperform with a $55 price target, citing an attractive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE